Evidence map›Paper›PMID 36135381›Full record

ArticleMicrobiology spectrum2022

Recombinant Actifensin and Defensin-d2 Induce Critical Changes in the Proteomes of Multidrug-Resistant Pseudomonas aeruginosa and Candida albicans.

Ifeoluwa D Gbala, Rosaline W Macharia, Joel L Bargul, Gabriel Magoma

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Ifeoluwa D GbalaMolecular Biology and Biotechnology, Pan African University, Institute for Basic Sciences, Technology, and Innovation, Juja, Kenya.ORCID 0000-0002-5123-8962
Rosaline W MachariaDepartment of Biochemistry, University of Nairobigrid.10604.33, Nairobi, Kenya.
Joel L BargulJomo Kenyatta University of Agriculture and Technologygrid.411943.a, Juja, Kenya.
Gabriel MagomaMolecular Biology and Biotechnology, Pan African University, Institute for Basic Sciences, Technology, and Innovation, Juja, Kenya.
International Centre of Insect Physiology and Ecology · KEJomo Kenyatta University of Agriculture and Technology · KEPan African University Institute for Basic Sciences, Technology and InnovationUniversity of Nairobi · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-resistant strains of Pseudomonas aeruginosa and Candida albicans pose serious threats to human health because of their propensity to cause fatal infections. Defensin and defensin-like antimicrobial peptides (AMPs) are being explored as new lines of antimicrobials, due to their broad range of activity, low toxicity, and low pathogen resistance. Defensin-d2 and actifensin are AMPs from spinach and Actinomyces ruminicola, respectively, whose mechanisms of action are yet to be clearly elucidated. This study investigated the mechanisms of action of the recombinant AMPs through label-free quantitative proteomics. The data are available at PRIDE with accession number PXD034169. A total of 28 and 9 differentially expressed proteins (DEPs) were identified in the treated P. aeruginosa and C. albicans, respectively, with a 2-fold change threshold and

Indexed as

Anti-Infective AgentsPseudomonas aeruginosaAdenosine TriphosphateAmino AcidsCandida albicansDefensinsHumansMicrobial Sensitivity TestsPeptidesProteomeProteomicsAdenosine TriphosphateAmino AcidsAnti-Infective AgentsDefensinsPeptidesProteomeactifensinantimicrobial mechanismantimicrobial peptidesCandida albicansproteomicsPseudomonas aeruginosaspinach defensin

Identifiers

PMID36135381
PMCPMC9602346
OpenAlexW4296613324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.